Article

Systemic Sclerosis (Also) Discriminates on Basis of Ethnicity

A study focusing on pulmonary complications finds far worse physical function and long-term prognosis among African American patients who have systemic sclerosis.

Blanco I, Mathai S, Shafiq M, et al.Severity of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in African Americans. Medicine (2014) 93: 177–185. doi: 10.1097/MD.0000000000000032

African Americans (AA) with systemic sclerosis (SSc) have a worse prognosis than Americans of European descent.

This study focused on the difference with regard to pulmonary comorbidities. It found that AA patients with pulmonary arterial hypertension (PAH) were more likely to present with severe PAH, to have diffuse SSc, and to have poorer survival odds.

The researchers studied 160 consecutive SSc patients with PAH diagnosed by right heart catheterization. The cohort included 29 Americans of African descent and 131 Americans of European descent. They had similar baseline characteristics,  except for increased prevalence of diffuse SSc among the AA patients.

AA patients had worse functional class, higher brain natriuretic peptide, more depressed right ventricular function, a trend toward lower 6-minute walk distance, and worse hemodynamics. Kaplan-Meier survival estimates for AA and European descent patients were 62% vs 73% at 2 years and 26% vs 44% at 5 years, respectively.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.